Cardiff Oncology, Inc.
Business
Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral, highly selective PLK1 inhibitor, in combination with standard-of-care therapeutics for cancer treatment. The company's lead program targets RAS-mutated metastatic colorectal cancer in a Phase 2 trial (CRDF-004) and is conducting investigator-initiated trials in metastatic pancreatic cancer, small cell lung cancer, triple-negative breast cancer, and chronic myelomonocytic leukemia. Cardiff operates as a single reportable segment, leveraging biomarker assays and tumor genomics to refine patient selection and assess treatment response across multiple solid tumor and hematologic indications.
Summary from 10-K filed 2026-02-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Royalty revenues | 593,000 | 683,000 | 488,000 | 386,000 | 359,000 | |
| Research and development | 35 | 37 | 33 | 27 | 17 | |
| Selling, general and administrative | 14 | 12 | 13 | 13 | 12 | |
| Total operating expenses | 50 | 49 | 46 | 40 | 29 | |
| Loss from operations | −49 | −49 | −45 | −40 | −29 | |
| Interest income | 3 | 3 | 4 | 2 | 264,000 | |
| Other income (expense), net | 5,000 | −39,000 | −98,000 | — | — | |
| Total other income (expense), net | 3 | 3 | 4 | 1 | 564,000 | |
| Net loss | −46 | −45 | −41 | −39 | −28 | |
| Preferred stock dividend payable on Series A Convertible Preferred Stock | −25,000 | −24,000 | −24,000 | −24,000 | −24,000 | |
| Net loss attributable to common stockholders | −46 | −45 | −41 | −39 | −28 | |
| Net loss per common share - basic | −0.69 | −0.95 | −0.93 | −0.89 | −0.73 | |
| Net loss per common share - diluted | −0.69 | −0.95 | −0.93 | −0.89 | −0.73 | |
| Weighted-average shares outstanding - basic | 67 | 48 | 45 | 44 | 39 | |
| Weighted-average shares outstanding - diluted | 67 | 48 | 45 | 44 | 39 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 17 | 51 | 22 | 16 | 12 | |
| Short-term investments | 41 | 40 | 53 | 89 | 129 | |
| Accounts receivable and unbilled receivable | 182,000 | 773,000 | 288,000 | 771,000 | 535,000 | |
| Prepaid expenses and other current assets | 2 | 3 | 2 | — | — | |
| Total current assets | 60 | 95 | 77 | 111 | 146 | |
| Property and equipment, net | 578,000 | 898,000 | 1 | 1 | 382,000 | |
| Operating lease right-of-use assets | 629,000 | 1 | 2 | 2 | 3 | |
| Other assets | 549,000 | 69,000 | 1 | 1 | 239,000 | |
| Total Assets | 62 | 97 | 82 | 116 | 150 | |
| Accounts payable | 8 | 5 | 2 | 2 | 1 | |
| Accrued liabilities | 8 | 8 | 8 | 5 | 5 | |
| Operating lease liabilities | 730,000 | 710,000 | 691,000 | 675,000 | 551,000 | |
| Total current liabilities | 16 | 13 | 10 | 8 | 7 | |
| Operating lease liabilities, net of current portion | 102,000 | 813,000 | 1 | 2 | 3 | |
| Total Liabilities | 16 | 14 | 12 | 10 | 9 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at December 31, 2025 and December 31, 2024 with liquidation preference of $1,117 and $1,092 at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 | 1,000 | |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,305 and 66,524 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 7,000 | 7,000 | 4,000 | 4,000 | 4,000 | |
| Additional paid-in capital | 475 | 467 | 409 | 405 | 401 | |
| Accumulated other comprehensive gain | 50,000 | 34,000 | −67,000 | −395,000 | −142,000 | |
| Accumulated deficit | −430 | −384 | −340 | −298 | −260 | |
| Total stockholders equity | 45 | 83 | 70 | 106 | 140 | |
| Total liabilities and stockholders equity | 62 | 97 | 82 | 116 | 150 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 364,000 | 404,000 | 398,000 | 236,000 | 451,000 | |
| Stock-based compensation expense | 6 | 5 | 5 | 4 | 3 | |
| Amortization of right-of-use assets | 540,000 | 539,000 | — | — | — | |
| Accretion of discounts on short-term investments, net | −848,000 | −598,000 | −921,000 | 632,000 | 2 | |
| Accounts receivable and unbilled receivable | 591,000 | −484,000 | 483,000 | −236,000 | −215,000 | |
| Prepaid expenses and other current assets | 557,000 | −452,000 | 3 | −443,000 | −2 | |
| Other assets | −480,000 | 1 | 108,000 | −1 | 166,000 | |
| Accounts payable and accrued liabilities | 2 | 3 | 3 | 1 | 719,000 | |
| Operating lease liabilities | −691,000 | −626,000 | −566,000 | −404,000 | −811,000 | |
| Net cash used in operating activities | −38 | −38 | −31 | −34 | −23 | |
| Capital expenditures | −44,000 | −80,000 | −582,000 | −1 | −205,000 | |
| Maturities of short-term investments | 71 | 27 | 87 | 76 | 28 | |
| Purchases of short-term investments | −72 | −24 | −70 | −91 | −174 | |
| Sales of short-term investments | 2 | 10 | 20 | 54 | 15 | |
| Net cash provided by investing activities | 1 | 14 | 36 | 38 | −131 | |
| Proceeds from sales of common stock, net of expenses of $0 and $3,286, respectively | 0 | 53 | — | 0 | 34 | |
| Proceeds from exercise of warrants, net of expense of $169 and $0, respectively | 2 | 0 | — | 0 | 1 | |
| Proceeds from exercise of options | 493,000 | 373,000 | 0 | 75,000 | 0 | |
| Net cash provided by financing activities | 3 | 54 | 0 | 75,000 | 35 | |
| Net change in cash and cash equivalents | −34 | 30 | 5 | 4 | −119 | |
| Cash paid for taxes | 1,000 | 1,000 | — | — | — | |
| Purchases of unsettled short-term investments included in accrued liabilities | 744,000 | 0 | 16,000 | 232,000 | 6,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cardiff Oncology, Inc.'s CIK number?
Cardiff Oncology, Inc.'s SEC CIK number is 0001213037 (1213037). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cardiff Oncology, Inc.'s SEC filings?
All of Cardiff Oncology, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cardiff Oncology, Inc. last report earnings?
Cardiff Oncology, Inc. (CRDF) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213037-26-000013). This is Cardiff Oncology, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cardiff Oncology, Inc.'s most recent earnings 8-K?
Cardiff Oncology, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001213037-26-000013. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cardiff Oncology, Inc.'s latest earnings 8-K →
Look up any company's CIK number →